UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000002339 |
|---|---|
| Receipt number | R000002865 |
| Scientific Title | Pharmacogenomics and pharmacokinetics study of drug metabolizing enzyme in patients with severe adverse drug reaction due to anti-neoplastics |
| Date of disclosure of the study information | 2009/08/14 |
| Last modified on | 2017/08/20 09:22:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Pharmacogenomics and pharmacokinetics study of drug metabolizing enzyme in patients with severe adverse drug reaction due to anti-neoplastics
Acronym
Pharmacogenomics and pharmacokinetics in patients with severe adverse drug reaction
Scientific Title
Pharmacogenomics and pharmacokinetics study of drug metabolizing enzyme in patients with severe adverse drug reaction due to anti-neoplastics
Scientific Title:Acronym
Pharmacogenomics and pharmacokinetics in patients with severe adverse drug reaction
Region
| Japan |
Condition
Condition
Cancer
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
Investigate pharmacogenomics and pharmacokinetics of drug metabolizing enzyme or transporter in patients with severe unpredicable adverse drug reaction
Basic objectives2
Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Genetic polymorphism
drug or metabolite concentration
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients with unpredictable severe adverse drug reaction including death due to anti-neoplastics
Key exclusion criteria
Informed consent not obtained
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroshi Ishiguro |
Organization
Graduate Schhol of Medicine Kyoto University
Division name
Department of Target Therapy Oncology
Zip code
Address
54 Syogoinkawahara-cho, Sakyo-ku, Kyoto-city
TEL
075-751-4950
hkkishi@kuhp.kyoto-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hiroshi Ishiguro |
Organization
Graduate Schhol of Medicine Kyoto University
Division name
Department of Target Therapy Oncology
Zip code
Address
54 Syogoinkawahara-cho, Sakyo-ku, Kyoto-city
TEL
075-751-4950
Homepage URL
hkkishi@kuhp.kyoto-u.ac.jp
Sponsor or person
Institute
Graduate Schhol of Medicine Kyoto University
Institute
Department
Personal name
Funding Source
Organization
Ministry of Education, Culture, Sports, Science and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
YES
Study ID_1
G-309
Org. issuing International ID_1
Kyoto University
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2009 | Year | 08 | Month | 14 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2009 | Year | 04 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 08 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
test genetic polymorphism and drug concentration
Management information
Registered date
| 2009 | Year | 08 | Month | 14 | Day |
Last modified on
| 2017 | Year | 08 | Month | 20 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002865
